Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Biofrontera (BFRI) EBIAT (2020 - 2025)

Biofrontera (BFRI) has 6 years of EBIAT data on record, last reported at -$6.6 million in Q3 2025.

  • For Q3 2025, EBIAT fell 17.29% year-over-year to -$6.6 million; the TTM value through Sep 2025 reached -$17.6 million, down 36.89%, while the annual FY2024 figure was -$17.8 million, 11.78% up from the prior year.
  • EBIAT reached -$6.6 million in Q3 2025 per BFRI's latest filing, down from -$5.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $5.6 million in Q1 2022 and bottomed at -$16.0 million in Q3 2021.
  • Average EBIAT over 5 years is -$4.9 million, with a median of -$4.2 million recorded in 2025.
  • Peak YoY movement for EBIAT: tumbled 7615.96% in 2021, then surged 257.36% in 2022.
  • A 5-year view of EBIAT shows it stood at -$14.5 million in 2021, then surged by 80.8% to -$2.8 million in 2022, then skyrocketed by 226.61% to $3.5 million in 2023, then crashed by 139.59% to -$1.4 million in 2024, then tumbled by 376.29% to -$6.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$6.6 million in Q3 2025, -$5.3 million in Q2 2025, and -$4.2 million in Q1 2025.